If you or a family member was harmed during a stroke procedure that used the Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology, you may have grounds for a Penumbra catheter lawsuit. Patients and surviving families have filed product liability claims alleging the device was defectively designed, that Penumbra knew about the dangers, and that it failed to warn doctors and patients in time. A separate federal securities class action, brought by an investor, is proceeding on a different track.
Who Can Bring a Claim
The lawsuits center on the JET 7 Xtra Flex, the version recalled in December 2020. Potential plaintiffs include people who suffered blood vessel damage, hemorrhage, stroke, or brain injury during a procedure in which that catheter was used, and families of patients who died.1ConsumerNotice.org. Penumbra JET 7 Xtra Flex Catheter Lawsuits
Two categories of records generally matter. Surgical notes have to confirm the JET 7 Xtra Flex was the device used, since the recall did not cover the JET 7 with Standard Tip, which used a different design and is still on the market.2Penumbra, Inc. Penumbra Announces JET 7 Reperfusion Catheter Voluntary Recall Medical records then have to document the injury that followed.1ConsumerNotice.org. Penumbra JET 7 Xtra Flex Catheter Lawsuits
What the Lawsuits Allege
The core allegation is that the JET 7 Xtra Flex had a defect at the distal tip, the end of the catheter that reaches the clot in the brain. During use, the tip could balloon outward, expand, or rupture inside a patient’s cerebral arteries.3Penumbra, Inc. JET 7 Xtra Flex Voluntary Recall Notification When contrast dye was injected through the catheter, a routine imaging step during stroke procedures, the pressurization could cause the tip to burst, leading to vessel damage, hemorrhage, and death.2Penumbra, Inc. Penumbra Announces JET 7 Reperfusion Catheter Voluntary Recall
Failures were not limited to contrast injections. One analysis of MAUDE adverse-event reports found that about 75% of reported malfunctions involved issues unrelated to contrast media, such as the catheter breaking or the distal tip sustaining damage on its own.4The Capitol Forum. Penumbra JET 7 Device Continues to Malfunction During Routine Use In some cases, the tip fractured entirely and lodged broken pieces inside a patient’s arteries, blocking further treatment.5PubMed Central. Penumbra JET 7 Reperfusion Catheter Case Series One MAUDE report described a 61-year-old stroke patient whose JET 7 tip expanded and broke during a thrombectomy; the internal carotid artery ruptured, a balloon catheter could not be advanced past the broken piece to stop the bleeding, and the patient died after 48 hours.6FDA. MAUDE Adverse Event Report 10440334
Legal claims typically include strict liability for design and manufacturing defects and failure to warn. Plaintiffs seek compensatory damages for medical costs, pain, and suffering, and punitive damages on the theory that Penumbra intentionally disregarded known risks.1ConsumerNotice.org. Penumbra JET 7 Xtra Flex Catheter Lawsuits
How Penumbra Is Expected to Defend the Cases
Penumbra’s likely defenses include arguing that patient deaths resulted from the underlying stroke rather than the catheter, that physicians used the device contrary to instructions (particularly by injecting contrast media after the July 2020 labeling change), and that the risk was statistically small relative to the more than 30,000 units distributed.3Penumbra, Inc. JET 7 Xtra Flex Voluntary Recall Notification
Publicly, the company took the same line before and during the recall. In response to short-seller allegations in late 2020, Penumbra called the claims “baseless” and said it was “unaware of a single patient death associated with the use of JET 7 Xtra Flex when it is used in line with the instructions for use.”7PR Newswire. Penumbra Responds to False Allegations From Short Sellers
The Recall That Drives the Claims
The JET 7 Xtra Flex was cleared by the FDA in June 2019. The first known death linked to the device was reported to the FDA in October 2019, four months later.8TCTMD. Penumbra’s JET 7 Recall: Kick-Start for Change In July 2020, Penumbra issued a safety notification and updated the labeling; in late August 2020, it obtained a new 510(k) clearance for labeling that explicitly warned against injecting contrast media through the catheter.9FDA. 510(k) Premarket Notification K202251
Reports of malfunctions continued. On December 15, 2020, Penumbra issued a voluntary recall of all configurations of the JET 7 Xtra Flex. Its own recall notice reported 239 adverse event reports, including 17 involving patient injury and 14 involving patient death attributed to distal tip damage, plus 11 additional injury reports for causes other than tip failure.3Penumbra, Inc. JET 7 Xtra Flex Voluntary Recall Notification The FDA classified the recall as Class I, its most serious category, and identified “process design” as the root cause. The recall was formally terminated in May 2024.10FDA. Class I Recall, Penumbra JET 7 Reperfusion Catheter
One point worth noting for anyone trying to work out whether their case is affected: passive surveillance systems like MAUDE rely on voluntary reporting, and researchers have estimated they capture only about 15% of actual adverse events.8TCTMD. Penumbra’s JET 7 Recall: Kick-Start for Change The official injury and death totals may understate the true number of patients affected.
The Investor Securities Class Action
The product liability cases are separate from the shareholder litigation. On January 15, 2021, investor Charles Williams filed a federal securities class action against Penumbra, CEO Adam Elsesser, and Executive Vice President Gita Barry in the U.S. District Court for the Northern District of California. The case is Williams v. Penumbra, Inc., Case No. 3:21-cv-00420, and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.11ClassAction.org. Williams v. Penumbra, Inc. et al.
The complaint covers a class period from August 3, 2020, through December 15, 2020, the date of the recall. It alleges Penumbra and its executives made materially false and misleading statements about the safety of the JET 7 Xtra Flex, failed to disclose known design defects, and publicly insisted the product was “absolutely safe” even as adverse events accumulated. When the recall was announced, the company’s stock dropped, and the suit claims investors suffered losses as a result.11ClassAction.org. Williams v. Penumbra, Inc. et al.
This case is for shareholders who bought Penumbra stock during the class period, not for injured patients. Patients and families pursue their claims through the individual product liability track described above.
Where Things Stand Now
As of mid-2026, no trials or settlements in the JET 7 product liability cases have been publicly reported, and the litigation appears to remain in early stages. The current status of the Williams securities case is not detailed in available records. Penumbra continues to operate and file regular reports with the SEC, and the JET 7 with Standard Tip, which was not part of the recall, remains on the market.2Penumbra, Inc. Penumbra Announces JET 7 Reperfusion Catheter Voluntary Recall
If you think a JET 7 Xtra Flex was used in your or a relative’s stroke procedure, request the operative report and imaging records from the hospital before contacting counsel. Those documents are what a product liability lawyer will need to evaluate whether the device, the injury, and the timing line up with the recalled product.